Published in final edited form as:

Spine (Phila Pa 1976). 2011 March 1; 36(5): E293–E300. doi:10.1097/BRS.0b013e3181ddd597.

Transforaminal Epidural Clonidine versus Corticosteroid for Acute Lumbosacral Radiculopathy due to Intervertebral Disk Herniation

Abram H. Burgher, M.D.^{*}, Bryan C. Hoelzer, M.D.[†], Darrell R. Schroeder, M.S.[‡], Gregory A. Wilson, R.R.T.[§], and Marc A. Huntoon, M.D.^{||}

^{*}Center for Pain and Supportive Care, Scottsdale, AZ

[†]Instructor in Anesthesiology, Mayo Clinic College of Medicine, Rochester, MN

[‡]Assistant Professor of Biostatistics, Mayo Clinic College of Medicine, Rochester, MN

[§]Research Coordinator, Department of Anesthesiology, Mayo Clinic, Rochester, MN

^{||}Associate Professor of Anesthesiology, Mayo Clinic College of Medicine, Rochester, MN

Abstract

Study Design—Randomized, double-blinded trial clinical trial.

Objective—To compare efficacies of 2 active therapies for chronic low back pain.

Summary of Background Data—Radicular pain may result from intervertebral disk herniation (IDH). Clonidine has demonstrated analgesic and antiinflammatory activity in animal studies of nerve injury. Extensive clinical experience supports neuraxial clonidine's safety.

Methods—Patients with ~3 months of low back and leg pain due to IDH were randomized to transforaminal epidural (TFE) injection(s) of 2% lidocaine and either clonidine (200 or 400mcg) or triamcinolone (40mg). Patients received 1- 3 injections administered about 2 weeks apart. Patients, investigators and study coordinators were blinded to treatment. Primary outcome was 11-point Pain Intensity Numerical Rating Scale (PI-NRS) at 1 month. Other outcomes included Patient Global Impression of Change (PGIC), and functional measures.

Results—Thirty-three patients were screened and randomized. Twenty-six patients enrolled; 11 received clonidine and 15 triamcinolone. Both groups showed significant improvement in pain score at 2 weeks and 1 month compared to baseline ($p < 0.05$). The corticosteroid group showed additional functional improvement at 1 month relative to clonidine ($p = 0.022$). There was no difference between groups for primary outcome. However, as target enrollment was not reached, we cannot say with confidence that the 2 treatments would be expected to result in similar short-term pain relief. Side-effects were common in both groups, but there were no serious complications.

Conclusions—Radicular pain due to IDH improved rapidly with TFE injection of either clonidine or triamcinolone. Corticosteroid resulted in greater functional improvement, with unclear differences in analgesia. Future studies will determine if clonidine is superior to placebo and of particular use in those at risk for corticosteroid complications.

Corresponding Author: Marc A. Huntoon, M.D., Mayo Clinic, Department of Anesthesiology, Division of Pain Medicine, 200 First St. SW, Rochester, MN 55905, huntoon.marc@mayo.edu, Telephone: (507) 284-2511, Fax: (507) 266-7732.

Will be Presented at: American Society of Anesthesiologists (ASA), Annual Meeting, Oct 17-21, 2009, New Orleans, LA

Introduction

Intervertebral disk herniation (IDH) leading to radiculopathy is a common clinical problem in western countries (1). Pain and other neurologic symptoms associated with this condition are likely a result of mechanical compression and local inflammation of spinal nerve-roots (2). Treatment methods include oral pain medications, physical therapy, epidural steroid injection (ESI) and surgery, among others. Both ESI and surgery appear to result in short-term pain relief relative to more conservative measures, yet neither is clearly superior to observation at 1-year follow-up (3,4). Moreover, corticosteroid administration is limited by systemic toxicity and rare but serious complications, while surgery is only moderately cost-effective, and requires hospitalization and postoperative recuperation (5,6).

Clonidine, originally developed as an antihypertensive, is approved by the United States Food and Drug Administration (FDA) for epidural administration in the treatment of cancer pain

([http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?](http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist)

[fuseaction=Search.Label_ApprovalHistory#apphist](http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist)). Multiple animal and human studies as well as clinical experience support the safety and potential efficacy of both neuraxial and perineural administration of clonidine (7-9). In addition to analgesia mediated by its action at α -2 adrenergic receptors located in the central and peripheral nervous system, clonidine may have anti-inflammatory activity that could influence pain by other mechanisms (7,10,11). In animal models, administration of clonidine at the site of mechanical or chemical nerve injury decreased hyperalgesia, modulated local cytokine expression and mitigated histologic changes seen with nerve injury (10,12-14).

Clonidine's safety record and dual action as an analgesic and anti-inflammatory agent in the setting of peripheral nerve injury make it an intriguing alternative to ESI for radicular pain. We hypothesized that clonidine administered in close proximity to the site of nerve injury in patients with spinal nerve-root displacement due to IDH would result in greater improvement in pain relative to corticosteroid. We investigated this hypothesis by comparing serial transforaminal epidural (TFE) injection of clonidine to triamcinolone using a randomized, double-blinded study design.

Methods

We conducted a single center, prospective study evaluating patients with ≤ 3 months of low back and leg pain due to IDH. The medical ethics committee for investigation of human subjects approved the study protocol prior to opening enrollment and the trial was registered at www.clinicaltrials.gov (NCT00588354). All patients provided written informed consent before study inclusion.

Patients

Eligible patients were 18 years or older, of either sex and local residents. Enrollment opened November, 2006 and closed November, 2008. Patients were evaluated at a multidisciplinary spine center or pain clinic at our institution where they were given a diagnosis of IDH with resultant low back $\leq$ leg pain due to encroachment of disk material on a spinal nerve-root as confirmed by computed tomography or magnetic resonance imaging. All patients had a positive nerve-root tension sign on physical examination with unilateral symptoms at a single level of the lumbosacral spine consistent with imaging findings.

Pain intensity was assessed for each patient using a numerical rating scale (PI-NRS) from 0 to 10 (0 is no pain and 10 is worst pain imaginable). Patients were excluded if pain was $< 3/10$ or $> 8/10$ if already taking opioids. Additional exclusion criteria were as follows:

history of recent spinal trauma; cauda equina syndrome; progressive motor deficit; chronic anticoagulation other than aspirin; infectious etiology; involvement in workers' compensation claim; history of adverse reaction to corticosteroids, local anesthetic or clonidine; history of one or more corticosteroid injection (equivalent to 40 mg or more of triamcinolone) in the preceding 4 months; pregnancy; or severe medical disease (e.g. uncontrolled diabetes mellitus or coronary disease).

Randomization, Blinding and Treatment

Using a block randomization scheme applied to all patients screened, patients were assigned to one group receiving transforaminal ESI with local anesthetic (40 or 80 milligrams triamcinolone diluted to 2 milliliters total volume with preservative-free normal saline, preceded by a test dose of 1 milliliter 2% lidocaine) or another receiving transforaminal epidural clonidine with local anesthetic (200 or 400 micrograms clonidine diluted to 2 milliliters total volume with preservative-free normal saline, preceded by a test dose of 1 milliliter 2% lidocaine). Those in the clonidine group were administered a lower dose at first injection and, if tolerated, received a higher dose at subsequent injections. Patients, investigators and all others with direct patient contact were blinded to treatment assignment. Only the research pharmacy at our institution knew treatment assignment. A syringe containing study drug (triamcinolone or clonidine) was provided by the pharmacy at each injection visit but contents of the syringe were masked. Patients were offered up to 3 injections and asked to commit to at least 1. The first injection was given on the day of enrollment and further injections were given at 10-14 day intervals. Injections were performed using fluoroscopic guidance and a transforaminal retroneural approach as described in the International Spine Intervention Society Practice Guidelines, 2004. Figures 1 and 2 are radiographs which demonstrate the technique. An institutional protocol including contrast-enhanced digital subtraction angiography was used to minimize risk of intravascular needle placement and confirm injectate spread along the nerve-root and into the epidural space at the target level. Before discharge, patients were monitored in a post-procedure setting for at least 60 minutes after injection.

Injections and other care dictated by study protocol were administered by a board certified pain management physician. Saved radiographic images from injections were reviewed by 2 of the investigators (A.H.B. and M.A.H.) prior to breaking the blind to verify correct needle placement. Patients were provided prescriptions or referrals for oral anti-inflammatories, oral anticonvulsant or antidepressant pain medications, oral opioid analgesics, physical therapy or more intensive medical or surgical therapy as indicated. Those experiencing worsening of pain as rated on the 0 to 10 PI-NRS at 1 month were offered rescue therapy, an unblinded fluoroscopically-guided transforaminal or interlaminar epidural injection containing 40 to 80 mg triamcinolone. A patient flow chart is shown (Figure 3).

Study Measures

Primary outcome measure was 11-point Pain Intensity Numerical Rating Scale (PI-NRS) at one month after enrollment. Other outcome measures were 7-point Patient Global Impression of Change (PGIC), Multidimensional Pain Inventory (MPI), Center for Epidemiologic Studies Depression Scale (CES-D), Roland-Morris Disability Questionnaire (RMDQ) and Oswestry Disability Index (ODI). Measures were examined at enrollment, immediately prior to 2nd injection (or 10-14 days after enrollment if only one injection administered) and immediately prior to 3rd injection (or 20-28 days after enrollment if <3 injections administered). Side-effects as reported by patients were recorded in an unedited format. Occurrence of surgery for the index pain generator was evaluated for up to 6 months after enrollment.

Statistical Analysis

Baseline characteristics were compared between groups using the rank sum test for continuous variables and an exact test for categorical variables. Treatment comparisons of the outcome variables were performed using analysis of covariance (ANCOVA) with treatment (clonidine vs steroid) as the independent variable and the baseline value included as a covariate. Within each treatment group, post-randomization measurements were compared to baseline using the paired t-test. The frequency of side effects and other binomial outcomes were compared between treatment groups using Fisher's exact test. In all cases, two-tailed p-values ≤ 0.05 were considered statistically significant.

Based on data from 2 clinical trials of patients with radiculopathy, we determined that a sample size of 20 patients in each group would provide statistical power (two-tailed, $\alpha=0.05$) to detect a difference of 2 points on the 11-point PI-NRS (15,16), allowing for drop-out of up to 15%. However, due to slow recruitment, a decision was made to discontinue enrollment after 26 patients had been enrolled. The decision to discontinue enrollment was made prior to breaking the blind or performing any data analysis. Given the reduced sample-size, treatment effects (clonidine versus steroid) are summarized using point-estimates and corresponding 95% confidence intervals.

Results

Baseline patient characteristics were similar between treatment groups (Table 1). Analyses of outcomes at 2-weeks and 4-weeks following randomization are summarized in Table 2. For each treatment group there was evidence of a significant (paired t-test $p<0.05$) improvement from baseline for PI-NRS at both 2-weeks and 4-weeks following randomization (Figure 4). However, for the primary endpoint of PI-NRS at 4-weeks following randomization, there was no significant difference between treatment groups (clonidine vs steroid treatment effect = +1.54, 95% C.I. -0.52 to +3.60; $p=0.159$). For the secondary endpoints of RMDQ and ODI there was evidence of a significant improvement from baseline at both 2-weeks and 4-weeks following randomization for the steroid group. For the clonidine group, these secondary endpoints tended to improve, but the changes from baseline were not statistically significant (paired t-test $p=0.062$ and $p=0.091$ for RMDQ at 2-weeks and 4-weeks; $p=0.171$ and $p=0.076$ for ODI at 2-weeks and 4-weeks). At 4 weeks following randomization, significant treatment effects were detected for RMDQ (clonidine vs steroid treatment effect = +5.67, 95% C.I. +1.22 to +10.12; $p=0.022$, Figure 2) and ODI (clonidine vs steroid treatment effect = +7.04, 95% C.I. +0.83 to +13.25; $p=0.038$). Results for RMDQ are shown (Figure 5). MPI did not differ significantly from baseline at 2-weeks or 4-weeks for either treatment group (paired t-test all $p>0.05$).

Sixty-seven percent of patients allocated to receive clonidine and 50% of those administered corticosteroid rated their course "much improved" ($\text{PGIC}\leq 2$) at 1-month, a difference that was not significant (Fisher's exact test $p=0.669$). Patients were allowed to receive up to 3 injections, a decision that depended both on patient desire and clinician recommendation. There were 22 and 34 total injections in the clonidine and corticosteroid groups, respectively. Two of eleven (18%) clonidine patients were administered all 3 injections, while 7/15 (47%) corticosteroid patients received 3 injections (Fisher's exact test $p=0.217$). At 6 months, 3 patients receiving clonidine and 1 patient receiving triamcinolone had undergone lumbar spine surgery (Fisher's exact test $p=0.279$). Side-effects were common, but none were serious and no patient required post-injection hospitalization due to side-effects (Table 3).

Discussion

This is the first clinical trial to examine TFE clonidine versus a similar injection of corticosteroid for the treatment of acute radicular pain due to IDH. Consistent with other clinical trials of epidural injection for lumbosacral radicular pain, patients in both groups showed short-term improvement after enrollment, with the corticosteroid group demonstrating additional functional improvement relative to clonidine at 1-month. To our knowledge, no previous randomized, blinded study has shown functional improvement with ESI relative to comparator treatment. We did not reach target enrollment as determined by a pre-study power analysis for the primary outcome PI-NRS at 1 month. As such, though we did not find a statistically-significant difference in pain relief between the 2 study arms, we cannot say with confidence that no difference exists.

Rationale

Radiculopathy associated with disk herniation is hypothesized to occur by 2 independent mechanisms: mechanical compression and cytokine-mediated radiculitis (2). Tumor necrosis factor-alpha (TNF- α) may be the cytokine of primary importance in the pathophysiology relating to the latter (17,18). Recently, Cohen et al. (2009) completed a randomized, blinded trial in which 18 patients received TFE injection of the TNF- α inhibitor etanercept for subacute to chronic lumbosacral radiculopathy due to IDH (19). At the 1-month primary outcome pain scores were lower in the etanercept subjects than in a small placebo group.

Clonidine is an attractive potential alternative therapy for IDH because it appears to be both analgesic and anti-inflammatory, is not expected to be associated with cumulative dose toxicity and has a long clinical track record of safety. Further, since clonidine is a non-particulate solution prior to injection, it may not carry the same risks of central nervous system infarction that have been attributed to particulate steroids injected *via* the TFE route (20,21). Clonidine's direct analgesic effect is primarily mediated through agonism at α -2 adrenergic receptors, which can be found on peripheral nerves, in the spinal cord and brainstem. Anti-inflammatory effects of clonidine have been noted in a number of preclinical studies of nerve injury, and may also indirectly influence pain (10,12-14). Clonidine reduced tissue content of cytokines, including TNF- α , in rats undergoing sciatic nerve ligation, particularly with serial administration (10). Other possible mechanisms for analgesia produced by clonidine as administered in our study exist, including blockade of C and A- δ fibers, increased potassium conductance, and augmentation of local anesthetic block (7).

Outcomes

Patients in our study demonstrated statistically- and clinically-significant improvement in pain score at both 2-weeks and 1-month after enrollment, regardless of group assignment (22,23). There were no significant differences between the study arms with regard to PI-NRS, PGIC, MPI, CES-D, number of injections or rate of surgery. However, patients in the corticosteroid group did show statistically-significant functional improvement (as measured on RMDQ and ODI) relative to clonidine at 1-month (23). Why the corticosteroid group exhibited functional improvement but no difference in other outcome measures relative to clonidine is not clear. The simplest explanation is that triamcinolone is superior to clonidine for IDH and that if our study were larger a difference in pain relief would have emerged. Other potential explanations exist, including that the pain rating, global change and pain interference measurement tools we used were not as sensitive as our functional measures or that clonidine's different pharmacodynamic profile results in an alternate mechanism leading to similar pain relief. For instance, clonidine may have weaker anti-inflammatory activity than corticosteroid but a stronger analgesic effect.

Carette et al. (1997) randomized patients with radicular pain due to IDH for <1 year to interlaminar epidural injection of methylprednisolone or saline. Pain scores on a 100-point visual analog scale fell an average of 21 and 12 points, respectively, 3 weeks after enrollment (15). We saw a mean decline of 2.9 and 4.6 points (on an 11-point scale) in the clonidine and triamcinolone groups, respectively, at 1 month, a difference suggestive of greater treatment effect in both of our groups relative to either group in Carette et al. (1997). ODI showed a greater mean reduction at 1 month in patients receiving triamcinolone (but not clonidine) in our study compared to either group in Carette et al. (1997) at 3 weeks. If these apparent differences are real, they could be due to a variety of factors, including different access route to the epidural space (interlaminar epidural space in Carette et al. (1997) versus TFE in our study), differences in symptom duration (longer in Carette et al. (1997)), or simply different outcome intervals. Rates of surgery vary widely among patients with lumbosacral radiculopathy, ranging from 15 to almost 45% at follow-up up to 2 years (15, 16, 24, 25). We recorded occurrence of surgery at 6 months among all patients enrolled and found an overall incidence of 4/26 (15%), with no difference between the study arms.

Side-effects were noted in both study groups but no serious complications occurred and no patient required hospital admission after injection. An escalating dosing schedule of clonidine was used so that any patient who noted clonidine-specific but not serious side-effects could remain in the study and continue to receive a relatively low clonidine dose. However, all patients who had more than 1 clonidine injection were administered the higher dose at subsequent injections. Interestingly, the complication we thought most likely in the clonidine group – hypotension – was seen in a single patient who was in the corticosteroid arm. This patient was not symptomatic and the hypotension resolved with fluid and extended stay in the outpatient area. One patient in the clonidine group withdrew from the study due to side-effects. This patient listed nausea and lightheadedness as the reason for withdrawal but did not decide to withdraw from the study until the 2-week follow-up visit. Overall, we had no indication that clonidine could not be safely administered in the outpatient setting using our dosing regimen.

Limitations

This study had a number of limitations. First, our hypothesis was that there would be a difference in the 2 study arms in pain score at 1-month after enrollment. We did not find a difference, but since we failed to reach target enrollment we cannot say with confidence that the study groups were similar with respect to primary outcome. We chose not to perform a *post hoc* power analysis. Our small sample size was also likely the cause of unequal distribution of subjects, with more patients assigned to receive corticosteroid than clonidine. Unfortunately, more screened patients who had been allocated to clonidine were deemed ineligible prior to enrollment.

Second, we chose clonidine because of its potential dual mechanism as an analgesic and anti-inflammatory. However, we did not measure analgesia during the expected analgesic peak of bolus epidural administration. Instead, we collected data 10 or more days after the last injection. Perhaps prolonged residence time at the site of nerve injury (e.g. continuous infusion, depot drug) or more frequent injection would have enhanced clonidine's effect (7). Currently, however, technological and cost limitations preclude more frequent or continuous administration of clonidine for the condition under study.

Third, we compared clonidine to an active control, rather than placebo. We cannot therefore comment on the efficacy relative to sham of either TFE clonidine or corticosteroid administered using our study protocol. Since the natural history of IDH is rapid improvement, results in either group cannot be stated to differ from that expected without interventional treatment among patients enrolled (3,26). However, we chose our study

design to provide practical evidence reflecting a subset of decisions clinicians must face (corticosteroid injection versus novel therapy). In addition, we thought it unfair to withhold active treatment since there is evidence of short-term symptomatic improvement with corticosteroid among patients similar to those enrolled in our trial (4).

Summary

Patients with acute radicular pain due to IDH demonstrated short-term improvement using a treatment approach which included either TFE corticosteroid or clonidine. There was no difference in pain score between the 2 study groups, a finding that could be at least partly due to the small number of patients enrolled. Clonidine administration resulted in no major adverse events, indicating that despite inferiority in our study, its risk-benefit profile may still be superior to corticosteroid in special populations at risk for corticosteroid-associated complications. Future studies should (1) compare clonidine to placebo, (2) consider additional outcome measures, (3) examine alternate dosing and injection intervals for clonidine and (4) include special populations at risk for steroid-associated complications.

Acknowledgments

The authors would like to acknowledge Carlos B. Mantilla, M.D.; Jose Alfredo Corredor Santos, M.D.; and the physicians and staff in the Division of Pain Medicine at Mayo Clinic, Rochester, MN.

Sources of Financial Support: The investigation was supported by a competitive funding grant from the National Center for Research Resources (NCRR), component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research, which was disbursed by our institution.

References

1. Deyo RA, Weinstein JN. Low back pain. *New England Journal of Medicine* 2001;344(5):363–70. see comment. [PubMed: 11172169]
2. Rhee JM, Schaufele M, Abdu WA. Radiculopathy and the herniated lumbar disc. Controversies regarding pathophysiology and management. *J Bone Joint Surg Am* 2006;88(9):2070–80. [PubMed: 17036418]
3. Weinstein JN, Lurie JD, Tosteson TD, et al. Surgical vs nonoperative treatment for lumbar disk herniation: the Spine Patient Outcomes Research Trial (SPORT) observational cohort. *JAMA* 2006;296(20):2451–9. see comment. [PubMed: 17119141]
4. Armon C, Argoff CE, Samuels J, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of N. Assessment: use of epidural steroid injections to treat radicular lumbosacral pain: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2007;68(10):723–9. see comment. [PubMed: 17339579]
5. Huntoon MA, Martin DP. Paralysis after transforaminal epidural injection and previous spinal surgery. *Regional Anesthesia & Pain Medicine* 2004;29(5):494–5. see comment. [PubMed: 15372396]
6. Tosteson AN, Skinner JS, Tosteson TD, et al. The cost effectiveness of surgical versus nonoperative treatment for lumbar disc herniation over two years: evidence from the Spine Patient Outcomes Research Trial (SPORT). *Spine* 2008;33(19):2108–15. [PubMed: 18777603]
7. Eisenach JC, De Kock M, Klimscha W. alpha(2)-adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984-1995). *Anesthesiology* 1996;85(3):655–74. [PubMed: 8853097]
8. Walker SM, Goudas LC, Cousins MJ, et al. Combination spinal analgesic chemotherapy: a systematic review. *Anesthesia & Analgesia* 2002;95(3):674–715. see comment. [PubMed: 12198058]
9. Reuben SS, Buvanendran A. Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques. *Journal of Bone & Joint Surgery - American Volume* 2007;89(6):1343–58.

10. Lavand'homme PM, Eisenach JC. Perioperative administration of the alpha2-adrenoceptor agonist clonidine at the site of nerve injury reduces the development of mechanical hypersensitivity and modulates local cytokine expression. *Pain* 2003;105(1-2):247–54. [PubMed: 14499442]
11. Wu CT, Jao SW, Borel CO, et al. The effect of epidural clonidine on perioperative cytokine response, postoperative pain, and bowel function in patients undergoing colorectal surgery. *Anesthesia & Analgesia* 2004;99(2):502–9. [PubMed: 15271731]
12. Liu B, Eisenach JC. Hyperexcitability of axotomized and neighboring unaxotomized sensory neurons is reduced days after perineural clonidine at the site of injury. *Journal of Neurophysiology* 2005;94(5):3159–67. [PubMed: 16222073]
13. Romero-Sandoval EA, McCall C, Eisenach JC. Alpha2-adrenoceptor stimulation transforms immune responses in neuritis and blocks neuritis-induced pain. *J Neurosci* 2005;25(39):8988–94. [PubMed: 16192389]
14. Romero-Sandoval A, Eisenach JC. Perineural clonidine reduces mechanical hypersensitivity and cytokine production in established nerve injury. *Anesthesiology* 2006;104(2):351–5. [PubMed: 16436856]
15. Carette S, Leclaire R, Marcoux S, et al. Epidural corticosteroid injections for sciatica due to herniated nucleus pulposus. *New England Journal of Medicine* 1997;336(23):1634–40. see comment. [PubMed: 9171065]
16. Karppinen J, Malmivaara A, Kurunlahti M, et al. Periradicular infiltration for sciatica: a randomized controlled trial. *Spine* 2001;26(9):1059–67. [PubMed: 11337625]
17. Olmarker K, Rydevik B, Nordborg C. Autologous nucleus pulposus induces neurophysiologic and histologic changes in porcine cauda equina nerve roots. *Spine* 1993;18(11):1425–32. see comment. [PubMed: 8235812]
18. Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. *Spine* 2001;26(8):863–9. [PubMed: 11317106]
19. Cohen SP, Bogduk N, Dragovich A, et al. Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. *Anesthesiology* 2009;110(5):1116–26. [PubMed: 19387178]
20. Tiso RL, Cutler T, Catania JA, et al. Adverse central nervous system sequelae after selective transforaminal block: the role of corticosteroids. *Spine J* 2004;4(4):468–74. [PubMed: 15246308]
21. Gazelka, HH.; Hoelzer, BC.; Huntoon, MA., et al. The effects of clonidine on particulate steroid size. American Society of Anesthesiologists, Annual Meeting; Oct 17-21, 2009; New Orleans, LA. 2009. submitted
22. Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. *Pain* 2001;94(2):149–58. [PubMed: 11690728]
23. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *J Pain* 2008;9(2):105–21. [PubMed: 18055266]
24. Riew KD, Yin Y, Gilula L, et al. The effect of nerve-root injections on the need for operative treatment of lumbar radicular pain. A prospective, randomized, controlled, double-blind study. *Journal of Bone & Joint Surgery - American Volume* 2000;82-A(11):1589–93.
25. Riew KD, Park JB, Cho YS, et al. Nerve root blocks in the treatment of lumbar radicular pain. A minimum five-year follow-up. *Journal of Bone & Joint Surgery - American Volume* 2006;88(8):1722–5.
26. Peul WC, van Houwelingen HC, van den Hout WB, et al. Surgery versus prolonged conservative treatment for sciatica. *New England Journal of Medicine* 2007;356(22):2245–56. see comment. [PubMed: 17538084]

Figure 1.

Antero-posterior radiographic view of needle in final position within the target neuroforamen. Radiographic contrast is seen along the nerve root and in the epidural space at the target vertebral segment.

Figure 2.

Lateral radiographic view of needle in final position within the target neuroforamen. Radiographic contrast is seen in the anterior epidural space, in close proximity to the putative site of nerve injury.

Figure 3.
Patient flow chart demonstrating enrollment, randomization and follow-up periods.

Figure 4.

Mean $\pm$ SD pain intensity numeric rating scale (PI-NRS) according to treatment group at baseline and also at 2-weeks and 4-weeks after randomization. The p-values presented for the 2-week and 4-week after randomization time periods correspond to the treatment effect from analysis of covariance (ANCOVA) with treatment (clonidine versus steroid) as the independent variable and the baseline value included as a covariate. For each treatment group, an asterisk (*) is used to denote significant differences from baseline (paired t-test $p < 0.05$).

Figure 5. Mean $\pm$ SD Roland Morris Disability Questionnaire (RMDQ) according to treatment group at baseline and also at 2-weeks and 4-weeks after randomization. The p-values presented for the 2-week and 4-week post randomization time periods correspond to the treatment effect from analysis of covariance (ANCOVA) with treatment (clonidine versus steroid) as the independent variable and the baseline value included as a covariate. For each treatment group, an asterisk (*) is used to denote significant differences from baseline (paired t-test $p < 0.05$).

Table 1

Baseline Patient Characteristics

	Clonidine (N=11)	Steroid (N=15)	p-value *
Age, years			0.161
Mean±SD	44.1±12.4	50.3±11.0	
Median (range)	40 (28 to 72)	49 (33 to 71)	
Gender			0.658
Male	9 (82)	10 (67)	
Female	2 (18)	5 (33)	
Level Injected, n (%)			0.865
L3	0 (0)	1 (7)	
L4	2 (18)	4 (27)	
L5	4 (36)	3 (20)	
S1	5 (45)	7 (47)	
Use of opioids, n (%)	10 (91)	10 (67)	0.197
Use of antiepileptics, n (%)	5 (45)	4 (27)	0.418
Duration of symptoms, weeks			0.649
Mean±SD	5.0±2.5	5.3±3.7	
Median (range)	4 (3 to 12)	4 (1 to 12)	
PI-NRS			0.751
Mean±SD	7.0±1.9	7.0±2.0	
Median (range)	7 (3 to 9)	7 (3 to 10)	
RMDQ			0.124
Mean±SD	14.0±3.8	11.0±5.2	
Median (range)	16 (7 to 19)	11 (3 to 19)	
ODI			0.153
Mean±SD	31.3±6.0	28.8±7.2	
Median (range)	33 (18 to 37)	27 (21 to 48)	
MPI			0.378
Mean±SD	56.9±12.7	52.9±9.1	
Median (range)	57.4 (37.7 to 74.1)	54.8 (29.1 to 65.6)	
CESD			0.979
Mean±SD	15.2±13.0	12.5±7.7	
Median (range)	11 (1 to 36)	14 (3 to 26)	

* Rank sum test for continuous variables, Fisher's exact test for categorical variables

Table 2

Treatment Effects at 2 and 4 Weeks Following Randomization*

	Estimate	(SE)	95% C.I.	p-value
Week 2				
PI-NRS	0.11	(0.97)	-1.79, 2.01	0.910
RMDQ	2.96	(2.04)	-1.04, 6.96	0.162
ODI	5.86	(3.28)	-0.57, 12.29	0.089
MPI	-4.83	(3.53)	-11.75, 2.09	0.186
Week 4				
PI-NRS	1.54	(1.05)	-0.52, 3.60	0.159
RMDQ	5.67	(2.27)	1.22, 10.12	0.022
ODI	7.04	(3.17)	0.83, 13.25	0.038
MPI	-0.35	(3.37)	-6.96, 6.26	0.918

* Data were analyzed separately for each measure using analysis of covariance with treatment (clonidine versus steroid) as the independent variable and the baseline value of the given measure included as a covariate. At 2 weeks data were available for 24 patients (9 clonidine, 15 steroid) and at 4 weeks data were available for 23 patients (9 clonidine, 14 steroid).

Table 3

Side Effects*

	Clonidine (N=11)	Steroid (N=15)
Discomfort at injection site	2 (18)	4 (27)
Worsening of symptoms	4 (36)	2 (13)
Lightheadedness	5 (45)	1 (7)
Drowsiness	2 (18)	3 (20)
Dry mouth	2 (18)	3 (20)
Weakness	4 (36)	1 (7)
Constipation	2 (18)	1 (7)
Nausea	1 (9)	2 (13)

* No patients required hospitalization for side effects. However, one patient in the clonidine group reported nausea and lightheadedness and discontinued study participation due to these side effects. The frequency of each side effect was compared between groups using Fisher's exact test with no significant ($p<0.05$) differences detected.